{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:21:55Z","timestamp":1772810515187,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1038\/ncponc0602","type":"journal-article","created":{"date-parts":[[2006,10,4]],"date-time":"2006-10-04T10:15:10Z","timestamp":1159956910000},"page":"552-563","source":"Crossref","is-referenced-by-count":26,"title":["Therapy Insight: parenteral estrogen treatment for prostate cancer\u2014a new dawn for an old therapy"],"prefix":"10.1038","volume":"3","author":[{"given":"Jeremy","family":"Ockrim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El-Nasir","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0602_CR1","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C and Hodges CV (1941) Studies on prostatic cancer I: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293\u2013297","journal-title":"Cancer Res"},{"key":"BFncponc0602_CR2","first-page":"263","volume":"20","author":"RM Nesbit","year":"1946","unstructured":"Nesbit RM and Plumb RT (1946) Prostatic carcinoma, follow-up on 795 patients treated prior to the endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery 20: 263\u2013272","journal-title":"Surgery"},{"key":"BFncponc0602_CR3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.1950.02910500019005","volume":"143","author":"RM Nesbit","year":"1950","unstructured":"Nesbit RM and Baum WC (1950) Endocrine control of prostatic carcinoma, clinical and statistical survey of 1518 cases. JAMA 143: 1317\u20131320","journal-title":"JAMA"},{"key":"BFncponc0602_CR4","unstructured":"The Veterans Administration Co-operative Urological Research Group 1967 (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011\u20131017"},{"key":"BFncponc0602_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9","volume":"26","author":"JC Bailar III","year":"1970","unstructured":"Bailar JC III and Byar DP (1970) Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 26: 257\u2013261","journal-title":"Cancer"},{"key":"BFncponc0602_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C","volume":"32","author":"DP Byar","year":"1973","unstructured":"Byar DP (1973) Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32: 1126\u20131130","journal-title":"Cancer"},{"key":"BFncponc0602_CR7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","volume":"83","author":"T Diamond","year":"1998","unstructured":"Diamond T et al. (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83: 1561\u20131566","journal-title":"Cancer"},{"key":"BFncponc0602_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW et al. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181\u2013186","journal-title":"J Urol"},{"key":"BFncponc0602_CR9","first-page":"657","volume":"21","author":"SD Fossa","year":"1994","unstructured":"Fossa SD et al. (1994) Assessment of quality of life in patients with prostate cancer. Semin Oncol 21: 657\u2013661","journal-title":"Semin Oncol"},{"key":"BFncponc0602_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0090-4295(01)01457-1","volume":"59","author":"GY Melmed","year":"2002","unstructured":"Melmed GY et al. (2002) Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 59: 103\u2013109","journal-title":"Urology"},{"key":"BFncponc0602_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199707313370502","volume":"337","author":"M Bolla","year":"1997","unstructured":"Bolla M et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295\u2013300","journal-title":"N Engl J Med"},{"key":"BFncponc0602_CR12","doi-asserted-by":"crossref","unstructured":"The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235\u2013246","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"BFncponc0602_CR13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","volume":"341","author":"EM Messing","year":"1999","unstructured":"Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781\u20131788","journal-title":"N Engl J Med"},{"key":"BFncponc0602_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0378-5122(99)00046-8","volume":"33","author":"V Mijatovic","year":"1999","unstructured":"Mijatovic V and Pines A (1999) The first clinical synthesis conference on hormone replacement therapy: new perspectives for HRT? Maturitas 33: 87\u201392","journal-title":"Maturitas"},{"key":"BFncponc0602_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1464-410X.1973.tb12238.x","volume":"45","author":"RJ Shearer","year":"1973","unstructured":"Shearer RJ et al. (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668\u2013677","journal-title":"Br J Urol"},{"key":"BFncponc0602_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0090-4295(84)80101-6","volume":"23","author":"PH Smith","year":"1984","unstructured":"Smith PH et al. (1984) Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762. Urology 23: 64\u201368","journal-title":"Urology"},{"key":"BFncponc0602_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-5347(17)45620-5","volume":"135","author":"HJ de Voogt","year":"1986","unstructured":"de Voogt HJ et al. (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303\u2013307","journal-title":"J Urol"},{"key":"BFncponc0602_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0090-4295(89)90106-4","volume":"33","author":"WB Peeling","year":"1989","unstructured":"Peeling WB (1989) Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33: 45\u201352","journal-title":"Urology"},{"key":"BFncponc0602_CR19","first-page":"111","volume":"303","author":"M Pavone-Macaluso","year":"1989","unstructured":"Pavone-Macaluso M et al. (1989) EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. Prog Clin Biol Res 303: 111\u2013116","journal-title":"Prog Clin Biol Res"},{"key":"BFncponc0602_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000475067","volume":"28","author":"MR Robinson","year":"1995","unstructured":"Robinson MR et al. (1995) The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 28: 273\u2013283","journal-title":"Eur Urol"},{"key":"BFncponc0602_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1464-410X.1989.tb06016.x","volume":"64","author":"MC Bishop","year":"1989","unstructured":"Bishop MC et al. (1989) Oestrogen dosage in prostatic cancer: the threshold effect? Br J Urol 64: 290\u2013296","journal-title":"Br J Urol"},{"key":"BFncponc0602_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0022-5347(01)66670-9","volume":"154","author":"RL Cox","year":"1995","unstructured":"Cox RL and Crawford ED (1995) Estrogens in the treatment of prostate cancer. J Urol 154: 1991\u20131998","journal-title":"J Urol"},{"key":"BFncponc0602_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pros.2990130308","volume":"13","author":"P Henriksson","year":"1988","unstructured":"Henriksson P et al. (1988) Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 13: 257\u2013261","journal-title":"Prostate"},{"issue":"Suppl 2","key":"BFncponc0602_CR24","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1097\/00000421-198801102-00024","volume":"11","author":"R Stege","year":"1988","unstructured":"Stege R et al. (1988) Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 11 (Suppl 2): S101\u2013S103","journal-title":"Am J Clin Oncol"},{"key":"BFncponc0602_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/pros.2990140211","volume":"14","author":"R Stege","year":"1989","unstructured":"Stege R et al. (1989) Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 14: 183\u2013188","journal-title":"Prostate"},{"key":"BFncponc0602_CR26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/01.ju.0000061024.75334.40","volume":"169","author":"JL Ockrim","year":"2003","unstructured":"Ockrim JL et al. (2003) Transdermal estradiol therapy for advanced prostate cancer\u2014forward to the past? J Urol 169: 1735\u20131737","journal-title":"J Urol"},{"key":"BFncponc0602_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.2990140210","volume":"14","author":"K Carlstrom","year":"1989","unstructured":"Carlstrom K et al. (1989) A comparison of androgen status in patients with prostatic cancer treated with oral and\/or parenteral estrogens or by orchidectomy. Prostate 14: 177\u2013182","journal-title":"Prostate"},{"key":"BFncponc0602_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/pros.2990140410","volume":"14","author":"B von Schoultz","year":"1989","unstructured":"von Schoultz B et al. (1989) Estrogen therapy and liver function\u2014metabolic effects of oral and parenteral administration. Prostate 14: 389\u2013395","journal-title":"Prostate"},{"key":"BFncponc0602_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1464-410X.1990.tb14728.x","volume":"65","author":"P Henriksson","year":"1990","unstructured":"Henriksson P et al. (1990) Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 65: 282\u2013285","journal-title":"Br J Urol"},{"key":"BFncponc0602_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000464045","volume":"17","author":"J Aro","year":"1990","unstructured":"Aro J et al. (1990) Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 17: 229\u2013235","journal-title":"Eur Urol"},{"key":"BFncponc0602_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/01.ju.0000165567.99142.1f","volume":"174","author":"JL Ockrim","year":"2005","unstructured":"Ockrim JL et al. (2005) Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174: 527\u2013533","journal-title":"J Urol"},{"key":"BFncponc0602_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","volume":"47","author":"PJ van Kesteren","year":"1997","unstructured":"van Kesteren PJ et al. (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47: 337\u2013342","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFncponc0602_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0002-9343(99)80130-2","volume":"99","author":"M Volterrani","year":"1995","unstructured":"Volterrani M et al. (1995) Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 99: 119\u2013122","journal-title":"Am J Med"},{"key":"BFncponc0602_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0378-5122(95)00997-3","volume":"23","author":"P Collins","year":"1996","unstructured":"Collins P (1996) Vascular aspects of oestrogen. Maturitas 23: 217\u2013226","journal-title":"Maturitas"},{"key":"BFncponc0602_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0090-4295(99)00580-4","volume":"55","author":"PO Hedlund","year":"2000","unstructured":"Hedlund PO and Henriksson P (2000) Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 55: 328\u2013333","journal-title":"Urology"},{"key":"BFncponc0602_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.1998.00688.x","volume":"82","author":"AK Mikkola","year":"1998","unstructured":"Mikkola AK et al. (1998) Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 82: 63\u201368","journal-title":"Br J Urol"},{"key":"BFncponc0602_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1043-2760(01)00406-4","volume":"12","author":"MP Bracamonte","year":"2001","unstructured":"Bracamonte MP and Miller VM (2001) Vascular effects of estrogens: arterial protection versus venous thrombotic risk. Trends Endocrinol Metab 12: 204\u2013209","journal-title":"Trends Endocrinol Metab"},{"key":"BFncponc0602_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1464-410X.2006.05937.x","volume":"97","author":"JL Ockrim","year":"2006","unstructured":"Ockrim JL et al. (2006) Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? BJU Int 97: 498\u2013504","journal-title":"BJU Int"},{"key":"BFncponc0602_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.publhealth.19.1.55","volume":"19","author":"E Barrett-Connor","year":"1998","unstructured":"Barrett-Connor E and Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Ann Rev Public Health 19: 55\u201372","journal-title":"Ann Rev Public Health"},{"key":"BFncponc0602_CR40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA 280: 605\u2013613","journal-title":"JAMA"},{"key":"BFncponc0602_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-135-1-200107030-00003","volume":"135","author":"F Grodstein","year":"2001","unstructured":"Grodstein F et al. (2001) Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 135: 1\u20138","journal-title":"Ann Intern Med"},{"key":"BFncponc0602_CR42","unstructured":"Emmans-Dean M et al. (2006) Parental oestrogens for prostate cancer: a systematic review of clinical effectiveness and dose response. Centre for Reviews and Dissemination. CRD Report 33; York: University of York"},{"key":"BFncponc0602_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/00365590510031228","volume":"39","author":"A Mikkola","year":"2005","unstructured":"Mikkola A et al. (2005) Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 39: 294\u2013300","journal-title":"Scand J Urol Nephrol"},{"key":"BFncponc0602_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/pros.2990180205","volume":"18","author":"J Aro","year":"1991","unstructured":"Aro J (1991) Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 18: 131\u2013137","journal-title":"Prostate"},{"key":"BFncponc0602_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/(SICI)1097-0045(19990701)40:2<76::AID-PROS2>3.0.CO;2-Q","volume":"40","author":"P Henriksson","year":"1999","unstructured":"Henriksson P et al. (1999) Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate 40: 76\u201382","journal-title":"Prostate"},{"key":"BFncponc0602_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/003655902762467549","volume":"36","author":"PO Hedlund","year":"2002","unstructured":"Hedlund PO et al. (2002) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scandinavian Prostatic Cancer Group (SPCG) Study No 5. Scand J Urol Nephrol 36: 405\u2013413","journal-title":"Scand J Urol Nephrol"},{"key":"BFncponc0602_CR47","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0022-5347(01)63223-3","volume":"159","author":"JH Wasson","year":"1998","unstructured":"Wasson JH et al. (1998) Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol 159: 1993\u20131996","journal-title":"J Urol"},{"key":"BFncponc0602_CR48","first-page":"288","volume":"76","author":"D Goldray","year":"1993","unstructured":"Goldray D et al. (1993) Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 76: 288\u2013290","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncponc0602_CR49","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948\u2013955","journal-title":"N Engl J Med"},{"key":"BFncponc0602_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878\u2013882","journal-title":"Lancet"},{"key":"BFncponc0602_CR51","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","volume":"169","author":"LJ Melton III","year":"2003","unstructured":"Melton LJ III et al. (2003) Fracture risk following bilateral orchiectomy. J Urol 169: 1747\u20131750","journal-title":"J Urol"},{"key":"BFncponc0602_CR52","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1097\/01.ju.0000145511.56476.00","volume":"172","author":"JL Ockrim","year":"2004","unstructured":"Ockrim JL et al. (2004) Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 172: 2203\u20132207","journal-title":"J Urol"},{"key":"BFncponc0602_CR53","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","volume":"152","author":"P Karling","year":"1994","unstructured":"Karling P et al. (1994) Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152: 1170\u20131173","journal-title":"J Urol"},{"key":"BFncponc0602_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0022-5347(05)65973-3","volume":"166","author":"AC Spetz","year":"2001","unstructured":"Spetz AC et al. (2001) Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166: 517\u2013520","journal-title":"J Urol"},{"key":"BFncponc0602_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0090-4295(99)00370-2","volume":"55","author":"GS Gerber","year":"2000","unstructured":"Gerber GS et al. (2000) Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55: 97\u2013101","journal-title":"Urology"},{"key":"BFncponc0602_CR56","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0090-4295(00)00823-2","volume":"56","author":"DG McLeod","year":"2000","unstructured":"McLeod DG and Iversen P (2000) Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 56: 713\u2013720","journal-title":"Urology"},{"key":"BFncponc0602_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000019548","volume":"33","author":"L Boccon-Gibod","year":"1998","unstructured":"Boccon-Gibod L (1998) Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol 33: 159\u2013164","journal-title":"Eur Urol"},{"key":"BFncponc0602_CR58","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","volume":"6","author":"S Perdona","year":"2005","unstructured":"Perdona S et al. (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6: 295\u2013300","journal-title":"Lancet Oncol"},{"key":"BFncponc0602_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00000421-199808000-00002","volume":"21","author":"MS Litwin","year":"1998","unstructured":"Litwin MS et al. (1998) Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21: 327\u2013332","journal-title":"Am J Clin Oncol"},{"key":"BFncponc0602_CR60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000020191","volume":"37","author":"SD Fossa","year":"2000","unstructured":"Fossa SD et al. (2000) Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C: results from the EORTC Phase-III trial 30893. Eur Urol 37: 541\u2013551","journal-title":"Eur Urol"},{"key":"BFncponc0602_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00434946","volume":"1","author":"BR Cassileth","year":"1992","unstructured":"Cassileth BR et al. (1992) Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1: 323\u2013329","journal-title":"Qual Life Res"},{"key":"BFncponc0602_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/1097-0142(19930201)71:3+<1143::AID-CNCR2820711437>3.0.CO;2-I","volume":"71","author":"HW Herr","year":"1993","unstructured":"Herr HW et al. (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71: 1143\u20131150","journal-title":"Cancer"},{"key":"BFncponc0602_CR63","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/jnci\/90.20.1537","volume":"90","author":"CM Moinpour","year":"1998","unstructured":"Moinpour CM et al. (1998) Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90: 1537\u20131544","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0602_CR64","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1200\/JCO.1999.17.7.2027","volume":"17","author":"F Boccardo","year":"1999","unstructured":"Boccardo F et al. (1999) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 17: 2027\u20132038","journal-title":"J Clin Oncol"},{"key":"BFncponc0602_CR65","volume-title":"Transdermal oestradiol therapy for the treatment of advanced prostate cancer [thesis]","author":"JO Ockrim","year":"2004","unstructured":"Ockrim JO (2004) Transdermal oestradiol therapy for the treatment of advanced prostate cancer [thesis]. London: University of London"},{"key":"BFncponc0602_CR66","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jnci\/92.21.1731","volume":"92","author":"AM Bayoumi","year":"2000","unstructured":"Bayoumi AM et al. (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92: 1731\u20131739","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0602_CR67","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0022-5347(05)65972-1","volume":"166","author":"PC Walsh","year":"2001","unstructured":"Walsh PC et al. (2001) A structured debate: immediate versus deferred androgen suppression in prostate cancer: evidence for deferred treatment. J Urol 166: 508\u2013515","journal-title":"J Urol"},{"key":"BFncponc0602_CR68","first-page":"532","volume":"174","author":"DL Trump","year":"2005","unstructured":"Trump DL (2005) Editorial comment. J Urol 174: 532\u2013533","journal-title":"J Urol"},{"key":"BFncponc0602_CR69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1464-410X.1990.tb14872.x","volume":"66","author":"R Haapiainen","year":"1990","unstructured":"Haapiainen R et al. (1990) Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 66: 94\u201397","journal-title":"Br J Urol"},{"key":"BFncponc0602_CR70","first-page":"5","volume":"206","author":"J Aro","year":"1993","unstructured":"Aro J et al. (1993) Polyestradiol phosphate (160 mg\/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. Ann Chir Gynaecol Suppl 206: 5\u20138","journal-title":"Ann Chir Gynaecol Suppl"},{"key":"BFncponc0602_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/00365599409180495","volume":"28","author":"O Lukkarinen","year":"1994","unstructured":"Lukkarinen O and Kontturi M (1994) Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma: an open prospective, randomized multicentre study. Scand J Urol Nephrol 28: 171\u2013178","journal-title":"Scand J Urol Nephrol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0602","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0602.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:43:59Z","timestamp":1684442639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["BFncponc0602"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0602","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}